These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 34585443

  • 1. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
    Black DM, Reid IR, Napoli N, Ewing SK, Shiraki M, Nakamura T, Takeuchi Y, Schafer AL, Kim TY, Cauley JA.
    J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
    [Abstract] [Full Text] [Related]

  • 2. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R.
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW.
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, Ota Y, Shiraki M.
    Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
    [Abstract] [Full Text] [Related]

  • 5. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA, HORIZON Pivotal Fracture Trial.
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [Abstract] [Full Text] [Related]

  • 6. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R.
    J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
    [Abstract] [Full Text] [Related]

  • 7. The role of zoledronic acid in the management of osteoporosis.
    Maricic M.
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [Abstract] [Full Text] [Related]

  • 8. The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients.
    Lu K, Wu YM, Shi Q, Gong YQ, Zhang T, Li C.
    Osteoporos Int; 2023 Sep; 34(9):1613-1623. PubMed ID: 37247006
    [Abstract] [Full Text] [Related]

  • 9. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R.
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [Abstract] [Full Text] [Related]

  • 10. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A.
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [Abstract] [Full Text] [Related]

  • 11. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
    Adachi JD, Lyles KW, Colón-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS.
    Osteoporos Int; 2011 Sep; 22(9):2539-49. PubMed ID: 21249332
    [Abstract] [Full Text] [Related]

  • 12. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW, HORIZON Recurrent Fracture Trial.
    J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
    [Abstract] [Full Text] [Related]

  • 13. Association between timing of zoledronic acid infusion and hip fracture healing.
    Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C, HORIZON Recurrent Fracture Trial.
    Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
    [Abstract] [Full Text] [Related]

  • 14. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M.
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [Abstract] [Full Text] [Related]

  • 15. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
    Chen FP, Fu TS, Lin YC, Lin YJ.
    Osteoporos Int; 2021 Apr; 32(4):663-670. PubMed ID: 33113007
    [Abstract] [Full Text] [Related]

  • 16. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 17. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR.
    Osteoporos Int; 2017 Jun 03; 28(6):1867-1874. PubMed ID: 28233020
    [Abstract] [Full Text] [Related]

  • 18. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.
    Magaziner JS, Orwig DL, Lyles KW, Nordsletten L, Boonen S, Adachi JD, Recknor C, Colón-Emeric CS, Mesenbrink P, Bucci-Rechtweg C, Su G, Johnson R, Pieper CF.
    J Bone Miner Res; 2014 Dec 03; 29(12):2545-51. PubMed ID: 24839241
    [Abstract] [Full Text] [Related]

  • 19. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP.
    J Bone Miner Res; 2011 Jan 03; 26(1):12-8. PubMed ID: 20645415
    [Abstract] [Full Text] [Related]

  • 20. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.
    Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H, Hiraishi K, Nakamura T.
    Calcif Tissue Int; 2021 Dec 03; 109(6):666-674. PubMed ID: 34247263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.